Table 4.
Determinants of leg lean mass Z-scores among CKD participants
| Difference in Leg LM Z-scores [95% CI] | P | |
|---|---|---|
| CKD category, versus CKD 2 to 3 | ||
| CKD 4 to 5 | −0.56 [−0.92, −0.21] | 0.002 |
| dialysis (versus CKD 2 to 3) | −1.31 [−1.73, −0.89] | <0.0001 |
| Leg length (per cm) | −0.06 [−0.09, −0.03] | <.0001 |
| Age (per year) | 0.04 [−0.03, 0.12] | 0.3 |
| Women (versus men) | −0.51 [−0.84, −0.18] | 0.003 |
| African American (versus non–African American) | 0.37 [0.02, 0.73] | 0.04 |
| Prepubertal (versus pubertal) | −0.51 [−1.03, 0.02] | 0.06 |
| Leg FM Z-score (per 1 SD increment) | 0.43 [0.31, 0.56] | <0.0001 |
| Renal diagnosis, versus CAKUT | ||
| glomerulonephritis | 0.75 [0.21, 1.29] | 0.007 |
| FSGS | 0.58 [0.13, 1.04] | 0.01 |
| other | −0.10 [−0.60, 0.39] | 0.7 |
| Current growth hormone use (versus no use) | 0.58 [0.03, 1.13] | 0.04 |
| Current glucocorticoid use (versus no use) | −0.42 [−1.06, 0.21] | 0.2 |
| CHOP (versus CCHMC) | −0.39 [−0.70, −0.07] | 0.02 |
We also considered the effect of interval since diagnosis of CKD, time on dialysis, physical activity (h/d), and serum levels of CRP, IL-6, albumin, and bicarbonate; however, none of these contributed significantly to the model.